National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Understanding Cancer Series: Estrogen Receptors/SERMs
< Back to Main
    Posted: 01/28/2005    Updated: 04/27/2006    Reviewed: 09/01/2006
Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Slide 17  :  Estrogen Receptor-Negative Breast Cancer <  >  

Unlike normal breast cells, cancer cells arising in the breast do not always have receptors for estrogen.

Breast cancers that DO have estrogen receptors are said to be "estrogen receptor-positive," while those breast cancers that DO NOT possess estrogen receptors are "estrogen receptor-negative." In women with estrogen receptor-positive cancers, cancer cell growth is under the control of estrogen. Therefore, such cancers are often susceptible to treatment with tamoxifen, because tamoxifen works by blocking the interaction between estrogen and the estrogen receptor.

In contrast, the growth of estrogen receptor-negative cancer cells is not governed by estrogen, or treated with tamoxifen.

Estrogen Receptor-Negative Breast Cancer

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov